Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Production in Russia (September, Q1–Q3 2021)

Thursday, October 28, 2021

In Q1–Q3 2021, Russian manufacturers produced RUB 432.7 billion worth of pharmaceutical drugs (manufacturer’s prices, VAT included), up 20% from the same period in 2020. Notable, the growth rates remain high for the third year in a row. In physical terms, the production volume was 2.98 billion packages; the growth rate was -16%. If calculated in minimum dosage units (MDU), the growth rate was -5.7%, and the production volume was 57.5 billion MDUs.

As for September 2021, the growth rate in monetary terms was +0.3%, which is the second best result this year. The total production volume was RUB 48 billion. In physical terms, the growth rates were negative: -24.4% in packages and -10% in MDUs. However, such modest results can be explained by the base effect in the past year, when September saw a peak in production due to an increase in the incidence of coronavirus infection. In addition, the range of manufactures products has changed significantly over the year; in particular, this year the pharmaceutical industry has reoriented itself to drugs that are more expensive.

The growth rates for Rx and OTC drugs in Q1–Q3 2021 remain uneven; in physical terms (packages), it was -21.4% for OTC drugs and -9.4% for Rx drugs.

Apart from a branch of the Gamaleya Research Institute of Epidemiology and Microbiology, Medgamal, no other top 20 manufacturer of Rx drugs had many-fold growth rates. At the same time, despite the decline in production, a number of companies managed to achieve a considerable gain. For example, Renewal increased its production 28% in packages. The production Anaprilin (increased 7 times from January–September 2020), Furosemide (3.7 times) and Piracetam (3.5 times) helped the company’s growth rates. Pharmasyntez had comparable results (+27% in packages) – thanks to a fundamentally different group of drugs, though. The production of the infusion form of levofloxacin, Bactoflox (3.9 times), and two hypoglycemic drugs Golda MB (2.7 times) and Merifatin (2.6 times) contributed to the growth rates the most.

As for OTC drugs, Valenta still has the highest growth rates in packages (+37%), with Trimedat and Ingavirin contributing to the success. Valenta is followed by Solopharm with +26%. The drugs that contributed to the growth rates were: Detriferol, a drug used to treat vitamin D deficiency (production increased 2.5 times from Q1–Q3 2021), and adaptogen Trekrezan (production doubled). Pharmstandard and Abbott, both of which increased their production by 25%, are also worth mentioning. Acetylsalicylic acid and Arbidol helped Pharmstandard’s growth rates; as for Abbott, it was Kreon and Duphalac.

Volumes of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (packages) and monetary terms (RUB, VAT included) (2016–2020, Q1–Q3 2021)